Hillstream BioPharma to Participate in Two Major Industry Conferences in April 2023
March 28 2023 - 8:47AM
Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the
"Company"), a biotechnology company developing therapeutic
candidates targeting drug resistant and devastating cancers using
ferroptosis, and immuno-oncology targeted novel biologics, today
announced that its CEO Randy Milby will be participating – in
person – at two major industry conferences in April 2023.
The Company will present at the 2023 BioNJ BioPartnering
Conference being held April 17-18, 2023 in Somerset, New Jersey.
Management will also attend the CPHI North America Conference being
held April 25-27, 2023 in Philadelphia, Pennsylvania. Management
will hold one-on-one meetings with analysts and qualified investors
at both conferences. Mr. Milby will also discuss recent operational
highlights, and updates on its immuno-oncology pipeline candidates,
including:
- Its lead drug candidate HSB-1216, utilizing ferroptosis, and
the outlook for initiating a clinical study in the second half of
2023.
- The Company’s emerging immune-oncology pipeline led by HSB-3215
which is an anti-HER2 monoclonal antibody.
“Both the CPHI North America and BioNJ BioPartnering conferences
are great opportunities to connect with investors and companies
from throughout the pharma sector. Networking with, and learning
from, our healthcare peers and executives from the US and globally
enables us to further our reach and accelerate our growth,” says
Randy Milby, CEO of Hillstream.
“Making a difference on behalf of patients, we are thrilled to
have HillStream BioPharma present its innovation at this year’s
BioPartnering Conference,” said BioNJ President and CEO Debbie
Hart. “It’s the perfect opportunity to meet new partners and
identify possible collaborations.”
To schedule a meeting with Hillstream management at either BioNJ
BioPartnering or CPHI North America, please send an email
to investorrelations@hillstreambio.com.
About BioNJ BioPartnering
BioNJ’s BioPartnering Conference will bring together over 500
life sciences executives, investors, academic collaborators and
business development professionals for networking, a full week of
1:1 partnering, company and start-up pitch presentations, exhibits
and plenary sessions. Attracting attendees from around the globe,
BioNJ’s BioPartnering Conference was created to foster productive
collaborations and partnerships, facilitate investment
opportunities, and bolster medical innovation.
For more information, please visit:
https://bionj.org/event/biopartnering-conference/.
About CPHI North America CPHI North America is
the premier event connecting the entire US pharmaceutical drug
development and manufacturing supply chain. The mission of CPHI
North America is to facilitate the growth and evolution of North
American pharma by providing a forum for innovation, learning,
sourcing and networking.
Part of the CPHI global network, the event being held April
25-27, 2023 at the Pennsylvania Convention Center in Philadelphia
brings together over 3,000 attendees from over 70 countries for 3
days of engaging and inspirational program content and unrivalled
networking opportunities.
For more information, please
visit: https://www.cphi.com/northamerica/en/home.html
About Hillstream BioPharma, Inc.Hillstream
BioPharma, Inc. is a biotechnology company developing therapeutic
candidates targeting drug resistant and devastating cancers using
ferroptosis, an emerging new anti-cancer mechanism resulting in
iron mediated cell death, and immuno-oncology targeted novel
biologics. The Company’s goal is to submit an investigational new
drug application and initiate a clinical study in the second half
of 2023, with HSB-1216 which targets ferroptosis, an emerging new
anti-cancer mechanism resulting in iron mediated cell death (IMCD)
of drug resistant cancers.
The Company’s emerging immuno-oncology pipeline is led by
HSB-3215 which is an anti-HER2 monoclonal antibody. The HER family
of cell surface proteins are some of the most well-known and
validated drug targets including HER2 and HER3.
The third candidate, HSB-1940 Quatrabody™, an anti-PD-1 novel
biologic which could be coated onto Quatramers, initiate clinical
studies in 2025. Hillstream’s Quatramer™ proprietary tumor
targeting platform extends duration of action and minimizes
off-target toxicity for biologics, mRNA, peptides, small molecules
and other modalities in the tumor microenvironment. Quatrabody
conjugates novel biologics developed against undruggable epitopes
of validated immuno-oncology targets, including PD-1, HER2, PDL-1
and TROP2 with greater binding affinity than approved
therapies.
For more information, please
visit: www.hillstreambio.com.
Investor Relations
ContactEmail: investorrelations@hillstreambio.comwww.hillstreambio.com
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From Sep 2023 to Sep 2024